Drug information provided by: Merative, Micromedex®
Umbralisib is used to treat marginal zone lymphoma (MZL) that has come back (relapsed) or did not respond to the treatment (refractory) in patients who have received at least one previous treatment (eg, anti-CD20-based treatment). It is also used to treat follicular lymphoma (FL) that has come back or did not respond to treatment in patients who have received at least 3 previous treatments.
This medicine is available only with your doctor's prescription.
This medicine was withdrawn from the U.S. market on June 1, 2022, due to safety concerns.
Portions of this document last updated: Feb. 01, 2023
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
A generous benefactor has pledged $1 million and challenged us to raise an additional $250,000. Help us reach our goal!